cbp-201
mAbexperimental
Clinical trial activity
10 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
8
Phase 3
1
Phase 4
0
Earliest trial started Jun 23, 2020 (NCT04444752)
Timeline
Indications
Mechanism of action
- Interleukin-4 receptor subunit alphaINHIBITOR
IL4R inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06940154 | Phase 2 | Aug 12, 2025 | Suzhou Connect Biopharmaceuticals |
| NCT06940141 | Phase 2 | Aug 8, 2025 | Suzhou Connect Biopharmaceuticals |
| NCT06701149 | Phase 1 | Nov 28, 2024 | Jinan University, Simcere Pharmaceutical Co., Ltd |
| NCT05917782 | Phase 1 | Jul 18, 2023 | Suzhou Connect Biopharmaceuticals |
| NCT05905133 | Phase 2 | Jul 15, 2023 | Suzhou Connect Biopharmaceuticals |
| NCT05614817 | Phase 3 | Dec 31, 2022 | Suzhou Connect Biopharmaceuticals |
| NCT05017480 | Phase 2 | Aug 31, 2021 | Suzhou Connect Biopharmaceuticals |
| NCT04783389 | Phase 2 | Jun 16, 2021 | Suzhou Connect Biopharmaceuticals |
| NCT04773678 | Phase 2 | May 11, 2021 | Suzhou Connect Biopharmaceuticals |
| NCT04444752 | Phase 2 | Jun 23, 2020 | Suzhou Connect Biopharmaceuticals |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Connect Biopharmaceuticals | For profit | 9 | 9 | 3 | 2020 |
| Jinan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Simcere Pharmaceutical Co., Ltd | For profit | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1